Prelude Therapeutics Incorporated
PRLD
$1.00
$0.117313.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -2.08% | 13.13% | -5.43% | -14.16% | -13.40% |
| Total Depreciation and Amortization | 2.11% | 47.73% | 45.16% | 60.85% | 53.24% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.83% | -41.07% | -1.24% | -24.25% | -29.19% |
| Change in Net Operating Assets | -32.08% | 15.33% | -0.76% | 240.01% | 41.74% |
| Cash from Operations | -7.68% | 12.02% | -6.28% | 16.67% | -5.50% |
| Capital Expenditure | 83.74% | 95.31% | 89.34% | 63.48% | 64.32% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.50% | 150.10% | -30.95% | 135.57% | 67.53% |
| Cash from Investing | 99.18% | 185.91% | -28.66% | 134.63% | 73.46% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -99.51% | -46.15% | -99.77% | -92.86% |
| Repurchase of Common Stock | 68.75% | -600.00% | 18.75% | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -128.28% | -- |
| Cash from Financing | -1,042.86% | -100.13% | -248.86% | -99.95% | 94.80% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 4,859.42% | -85.74% | -58.24% | -62.15% | 95.29% |